In this case study, a non-small cell lung cancer patient harboring EML4-ALK demonstrated an initial response to treatment with Crizotinib, but subsequently demonstrated resistance following the acquisition of the ALK C1156Y mutation (top left). The gene discussed is EML4; the disease is non-small cell lung carcinoma.